{"disease":{"id":"treatment-of-non-muscle-invasive-bladder-cancer-nmibc-with-carcinoma-in-situ-cis","name":"treatment of non muscle invasive bladder cancer nmibc with carcinoma in situ cis"},"drugs":{"marketed":[{"drug_id":"bcg","indication_name":"Treatment of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tice Bcg","generic_name":"bcg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"BCG targets the immune system, specifically the activation of immune cells such as T-cells and macrophages.","drug_class":"Live Attenuated Bacillus Calmette-Guerin Vaccine [EPC]","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"bcg","guideline_body":"FDA label","recommendation":"TICE BCG is indicated for the treatment of non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS).","line_of_therapy":"1L","evidence_grade":"not specified","guideline_year":null}],"source":"Drug Landscape verified database"}